This study assessed the effectiveness of combining atezolizumab, bevacizumab, pemetrexed and carboplatin/cisplatin for EGFR‐mutated NSCLC patients resistant to EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.